Exciting News Sent By Nikolina Lauc (WEACE 2020) CEO GlycanAge:
"Over the last year (our first commercial year) we discovered an unexpected application of our existing technology that was missed by 50+ scientists in its research lab; the first accurate diagnostics test for perimenopause and menopause. We conducted a retrospective study in collaboration with King's College London, analysing a sample of 1,940 twins, validating and patenting its application. Technically speaking, our test is the first HbA1c-type predictive biomarker for peri/menopause. We are currently gathering real world evidence in collaboration with the largest menopause specialists clinic in the world and passing through the final stages of IVDD CE regulatory approval, placing it on the UK market in 2022."